Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: a scoping review
In:
Contributors (4)
Christensen, Mikkel Bring (
0000-0002-8774-1797)
[1]
[2]
Affiliations
- [1] Department of Clinical Pharmacology, Bispebjerg and Frederiksberg University Hospital
- [2] University of Copenhagen [NORA names: KU University of Copenhagen; University; Denmark; Europe, EU; Nordic; OECD]
Abstract
Summary As obesity continues to be a global health challenge presenting various negative impacts on health outcomes and healthcare costs, there is a growing need for pharmacological interventions to address the issue. Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes, but there is a lack of studies comparing adverse events across different populations. This review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals for treating overweight or obesity in adults, adolescents, and children.
Keywords
adolescents,
adults,
adverse events,
agonists,
challenges,
children,
cost,
diabetes,
different populations,
events,
global health challenge,
glucagon-like peptide-1 receptor agonists,
health challenges,
health outcomes,
healthcare costs,
impact,
intervention,
issues,
lack,
lack of studies,
management,
need,
negative impact,
obesity,
outcomes,
overweight,
peptide-1 receptor agonists,
pharmaceuticals,
pharmacological interventions,
population,
potential,
receptor agonist,
review,
risk,
safety,
study,
summary,
type 2 diabetes,
weight management
